Table 3.
Association between therapeutic response and molecular biomarkers.
| Total | Therapeutic response | p value | ||
|---|---|---|---|---|
| Incomplete response, N (%) | Complete response, N (%) | |||
| Ki67 | 57 | 0.620 | ||
| <50 | 16 (88.9) | 2 (11.1) | ||
| ≥50 | 34 (87.2) | 5 (12.8) | ||
| MSI | 57 | 0.220 | ||
| Unstable | 9 (81.8) | 2 (18.2) | ||
| Stable | 41 (89.1) | 5 (10.9) | ||
| MSH6 | ||||
| Stable | 57 | 47 (87) | 7 (13) | 0.100 |
| Unstable | 3 (100) | 0 (0) | ||
| MSH2 | 57 | |||
| Stable | 48 (88.9) | 6 (11.1) | 0.330 | |
| Unstable | 2 (66.7) | 1 (33.3) | ||
| MLH1 | 57 | |||
| Stable | 48 (88.9) | 6 (11.1) | 0.330 | |
| Unstable | 2 (66.7) | 1 (33.3) | ||
| PMS2 | 57 | |||
| Stable | 47 (88.7) | 6 (11.3) | 0.417 | |
| Unstable | 3 (75) | 1 (25) | ||
| KRAS exon 2 | 57 | |||
| Wild type | 35 (85.4) | 6 (14.6) | 0.660 | |
| Mutated | 15 (93.8) | 1 (6.3) | ||
| KRAS exon 3 | 50 | |||
| Wild type | 44 (88) | 6 (12) | ∗ | |
| Mutated | 0 (0) | 0 (0) | ||
| KRAS exon 4 | 51 | |||
| Wild type | 42 (89.4) | 5 (10.6) | 1.000 | |
| Mutated | 4 (100) | 0 (0) | ||
| NRAS exon 2 | 47 | |||
| Wild type | 41 (89.1) | 5 (10.9) | 1.000 | |
| Mutated | 1 (100) | 0 (0) | ||
| NRAS exon 3 | 57 | |||
| Wild type | 49 (87.5) | 7 (12.5) | 1.000 | |
| Mutated | 1 (100) | 0 (0) | ||
| NRAS exon 4 | 47 | ∗ | ||
| Wild type | 40 (90.9) | 4 (9.1) | ||
| Mutated | 0 (0) | 0 (0) | ||
| HER-2 scoring | 57 | |||
| 0 | 37 (86) | 6 (14) | 0.810 | |
| 1 | 7 (87.5) | 1 (12.5) | ||
| 2 | 3 (100) | 3 (100) | ||
| 3 | 3 (100) | 0 (0) | ||
| p53 | 57 | 0.002 | ||
| <20 | 6 (100) | 0 (0.0) | ||
| 20-50 | 4 (50) | 4 (50) | ||
| ≥50 | 40 (93) | 3 (7) | ||
∗ p value was not calculated because the variable is constant.